newsfilter
← Latest News
GlobeNewswire·

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE:CHRO) ("Chromocell" or the "Company"), a clinical-stage biotech company focused on developing and commercializing new,